Twist Bioscience Announces $300 Million Public Offering of Common Stock

Details

The offering, which is expected to close on August 6, 2026, is being made pursuant to the company's automatic shelf registration statement on Form S-3. The net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $327.1 million and will be used for research and development investments, expansion of manufacturing capacity, product offerings, and other general corporate purposes. Goldman Sachs & Co. LLC, William Blair, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers for the offering.

Items reported

About Twist Bioscience Corporation

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.